{"filing":{"accession_number":"0001193125-26-286955","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d145470d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000119312526286955/d145470d6k.htm"},"events":[{"id":14509,"run_id":12922,"accession_number":"0001193125-26-286955","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces the completion of Optimi's third commercial psilocybin export shipment to Australia (1,000 capsules of 5mg psilocybin for treatment-resistant depression), marking ongoing commercial revenue generation from a regulated market. The disclosure emphasizes the company's commercial-stage operations, expanding reimbursement coverage from public and private insurers, and the absence of serious adverse events. While this is an operational milestone reflecting the company's ability to execute its business model in a regulated psychedelic medicine market, it does not fit the discrete event categories (M\u0026A, earnings release, executive changes, debt issuance, etc.) and is best classified as an operational business development event.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":11973,"accession_number":"0001193125-26-286955","item_number":"EX-99.1","item_title":"d145470dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the completion of Optimi's third commercial psilocybin export shipment to Australia (1,000 capsules of 5mg psilocybin for treatment-resistant depression), marking ongoing commercial revenue generation from a regulated market. The disclosure emphasizes the company's commercial-stage operations, expanding reimbursement coverage from public and private insurers, and the absence of serious adverse events. While this is an operational milestone reflecting the company's ability to execute its business model in a regulated psychedelic medicine market, it does not fit the discrete event categories (M\u0026A, earnings release, executive changes, debt issuance, etc.) and is best classified as an operational business development event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:01:38.437158+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11973,"accession_number":"0001193125-26-286955","item_number":"EX-99.1","item_title":"d145470dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the completion of Optimi's third commercial psilocybin export shipment to Australia (1,000 capsules of 5mg psilocybin for treatment-resistant depression), marking ongoing commercial revenue generation from a regulated market. The disclosure emphasizes the company's commercial-stage operations, expanding reimbursement coverage from public and private insurers, and the absence of serious adverse events. While this is an operational milestone reflecting the company's ability to execute its business model in a regulated psychedelic medicine market, it does not fit the discrete event categories (M\u0026A, earnings release, executive changes, debt issuance, etc.) and is best classified as an operational business development event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:01:38.437158+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-06-29"}]}